FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Prause Burkhard
2. Issuer Name and Ticker or Trading Symbol

BRUKER CORP [ BRKR ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Pres. & CEO, Bruker EST
(Last)          (First)          (Middle)

BRUKER CORPORATION, 40 MANNING ROAD
3. Date of Earliest Transaction (MM/DD/YYYY)

9/5/2019
(Street)

BILLERICA, MA 01821
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  9/5/2019    S    15702  D $42.96  1338  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Prause Burkhard
BRUKER CORPORATION
40 MANNING ROAD
BILLERICA, MA 01821


Pres. & CEO, Bruker EST

Signatures
/s/Michael Rich, Attorney-in-Fact 9/9/2019
**Signature of Reporting Person Date


Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Bruker Charts.
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Bruker Charts.

Bruker Corp News

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Bruker Completes Acquisition of Molecular Diagnostics Innovator ELITech
Thursday 2 May 2024 (2 days ago) • Business Wire
Bruker Further Enhances Clinical Microbiology & Infection Diagnostics Portfolio at ESCMID Global 2024 Conference
Friday 26 April 2024 (1 week ago) • Business Wire
Bruker Announces Date and Time of First Quarter 2024 Earnings Release and Webcast
Friday 26 April 2024 (1 week ago) • Business Wire
Bruker to Acquire the NanoString Business in an Asset Deal
Monday 22 April 2024 (2 weeks ago) • Business Wire
Bruker Introduces Novel NMR Scientific Capabilities for Structural Biology Discoveries in Membrane Proteins and Protein Aggregates
Monday 8 April 2024 (4 weeks ago) • Business Wire
Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research
Thursday 4 April 2024 (4 weeks ago) • GlobeNewswire Inc.
Bruker Selected as ‘Company of the Year’ by Instrument Business Outlook
Monday 1 April 2024 (1 month ago) • Business Wire
Bruker Advances CCS-Enabled 4D-Proteomics timsTOF Solutions for Immunopeptidomes and Glycoproteomics at US HUPO
Monday 11 March 2024 (2 months ago) • Business Wire
Bruker Announces Closing of Chemspeed Technologies AG Acquisition
Thursday 7 March 2024 (2 months ago) • Business Wire
Form 4 - Statement of changes in beneficial ownership of securities
Thursday 7 March 2024 (2 months ago) • Edgar (US Regulatory)
Form 144 - Report of proposed sale of securities
Tuesday 5 March 2024 (2 months ago) • Edgar (US Regulatory)
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Friday 1 March 2024 (2 months ago) • Edgar (US Regulatory)